34 related articles for article (PubMed ID: 2959199)
1. Cefetamet pivoxil clinical pharmacokinetics.
Blouin RA; Stoeckel K
Clin Pharmacokinet; 1993 Sep; 25(3):172-88. PubMed ID: 8222459
[TBL] [Abstract][Full Text] [Related]
2. Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Bryson HM; Brogden RN
Drugs; 1993 Apr; 45(4):589-621. PubMed ID: 7684677
[TBL] [Abstract][Full Text] [Related]
3. Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
Balfour JA; Todd PA; Peters DH
Drugs; 1995 May; 49(5):794-850. PubMed ID: 7601015
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone antimicrobial agents.
Wolfson JS; Hooper DC
Clin Microbiol Rev; 1989 Oct; 2(4):378-424. PubMed ID: 2680058
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya.
MacDonald KS; Cameron DW; D'Costa L; Ndinya-Achola JO; Plummer FA; Ronald AR
Antimicrob Agents Chemother; 1989 May; 33(5):612-4. PubMed ID: 2502065
[TBL] [Abstract][Full Text] [Related]
6. Fleroxacin clinical pharmacokinetics.
Stuck AE; Kim DK; Frey FJ
Clin Pharmacokinet; 1992 Feb; 22(2):116-31. PubMed ID: 1551289
[TBL] [Abstract][Full Text] [Related]
7. Correlation between in vitro antimicrobial susceptibilities and beta-lactamase plasmid contents of isolates of Haemophilus ducreyi from the United States.
Motley M; Sarafian SK; Knapp JS; Zaidi AA; Schmid G
Antimicrob Agents Chemother; 1992 Aug; 36(8):1639-43. PubMed ID: 1416845
[TBL] [Abstract][Full Text] [Related]
8. The plasmids of Haemophilus ducreyi.
McNicol PJ; Ronald AR
J Antimicrob Chemother; 1984 Dec; 14(6):561-4. PubMed ID: 6440883
[No Abstract] [Full Text] [Related]
9. Antimicrobial susceptibility of Haemophilus ducreyi.
Dangor Y; Ballard RC; Miller SD; Koornhof HJ
Antimicrob Agents Chemother; 1990 Jul; 34(7):1303-7. PubMed ID: 2201248
[No Abstract] [Full Text] [Related]
10. In vitro activity of ceftriaxone, cefetamet (Ro 15-8074), ceftetrame (Ro 19-5247; T-2588), and fleroxacin (Ro 23-6240; AM-833) versus Neisseria gonorrhoeae and Haemophilus ducreyi.
Le Saux NM; Slaney LA; Plummer FA; Ronald AR; Brunham RC
Antimicrob Agents Chemother; 1987 Jul; 31(7):1153-4. PubMed ID: 2959199
[TBL] [Abstract][Full Text] [Related]
11. The activity of the 4 quinolone Ro 23 6240 and the cephalosporins Ro 15 8074 and Ro 19 5247 against penicillin sensitive and resistant gonococci.
Easmon CS; Woodford N; Ison CA
J Antimicrob Chemother; 1987 Jun; 19(6):761-5. PubMed ID: 3112100
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of RO 15-8074 and RO 19-5247.
Valle T; Jalanko E; Scheinin L; Renkonen OV
Eur J Clin Microbiol; 1987 Apr; 6(2):167-9. PubMed ID: 3109897
[TBL] [Abstract][Full Text] [Related]
13. Activity of Ro 236240, Ro 158074 and Ro 195247 against resistant gonococci.
Easmon CS; Woodford N; Ison CA
Chemioterapia; 1987 Jun; 6(2 Suppl):156. PubMed ID: 3151337
[No Abstract] [Full Text] [Related]
14. In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis.
Bowie WR; Shaw CE; Chan DG; Black WA
Antimicrob Agents Chemother; 1987 Mar; 31(3):470-2. PubMed ID: 2953304
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
